Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest ALS Stories

2013-04-17 08:29:40

Trial Expands to Two Centers; Approval Includes Significant Increase in Dosing ROCKVILLE, Md., April 17, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This Phase II dose escalation and safety trial will expand to two centers,...

2013-04-15 12:25:46

Event Honored Entertainment Icons and Raised Funds for Cleveland Clinic Lou Ruvo Center for Brain Health LAS VEGAS, April 15, 2013 /PRNewswire/ -- Some of the biggest names in the entertainment industry celebrated the 80(th) birthday of Quincy Jones and Sir Michael Caine Saturday, April 13 at the 17(th) annual Keep Memory Alive Power of Love Gala at MGM Grand Garden Arena in Las Vegas. The star-studded event raised funds for Cleveland Clinic Lou Ruvo Center for Brain Health and its...

2013-04-12 08:28:22

NORDBORG, Denmark, April 12, 2013 /PRNewswire/ -- Danfoss A/S announced today that its tender offer to purchase all the issued and outstanding shares of Sauer-Danfoss Inc. (NYSE: SHS) not already owned by Danfoss for $58.50 per share in cash was successful. The tender offer expired at 12:00 midnight, New York City time, on Thursday, April 11, 2013. The depositary for the tender offer has advised that, as of such time, a total of 9,864,864 shares were validly tendered and not...

2013-04-12 08:25:18

Patent-pending PRCN-829 delivers multiple genes, including Factor H, neural growth factors and regulators of TDP-43 to treat neurodegenerative disease ALS BOGOTA, Colombia, April 12, 2013 /PRNewswire/ -- Startup biotechnology company Neuralgene (http://neuralgene.com) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment of amyotrophic lateral sclerosis (ALS). PRCN-829 is the first gene therapy...

2013-04-10 11:35:03

ALS drug effects highlights potassium channel role There is no specific drug to treat spinal muscular atrophy (SMA), a family of motor neuron diseases that in its most severe form is the leading genetic cause of infant death in the United States and affects one in 6,000 people overall. But a new multispecies study involving a drug that treats amyotrophic lateral sclerosis (ALS) has pinpointed a mechanism of SMA that drug developers might be able to exploit for a new therapy. The...

2013-04-05 08:23:51

ROCKVILLE, Md., April 5, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it received a notice of allowance for patent application 12/404,841. This patent covers methods for treating amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) with expanded spinal cord stem cells, including NSI-566. Neuralstem completed a Phase I safety trial of its NSI-566 stem cells in ALS earlier this year, for which it has also been granted an Orphan Drug Designation. The company...

2013-04-03 08:29:38

WASHINGTON, April 3, 2013 /PRNewswire-USNewswire/ -- April is National Volunteer Month, and The ALS Association is recognizing the important role volunteers play in the lives of people living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The disease robs people of the ability to walk, to talk and even blink an eye. It traps them inside a body they no...

2013-04-02 16:25:24

Rockefeller Plaza Exhibit Highlights Hope for the Growing Health Concern NEW YORK, April 2, 2013 /PRNewswire/ -- As the leader for research in ALS, the devastating brain disorder also known as Lou Gehrig's disease, Project A.L.S. has been selected by EHE International to raise awareness about ALS and related brain diseases in a 103-square foot window display in Rockefeller Plaza. The interactive Project A.L.S. exhibit debuts today in the major international thoroughfare, and will be...

2013-04-02 12:46:05

The most common genetic cause of both ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) was recently identified as an alteration in the gene C9orf72. But how the mutation causes neurodegenerative disease appeared mysterious. Researchers at Emory University School of Medicine have demonstrated that this ALS/FTD mutation may be harmful because it creates an "RNA sponge," soaking up an important regulatory protein that binds RNA. The results were published online Monday...

2013-04-02 08:21:43

WASHINGTON, April 2, 2013 /PRNewswire-USNewswire/ -- In work supported by The ALS Association and funded through its Milton Safenowitz Post-Doctoral Fellowship Program, researchers in Baltimore, Md., have shown that cells that normally support neurons in the spinal cord instead worsen the disease in an animal model of amyotrophic lateral sclerosis (ALS). The study was published in the journal Nature Neuroscience on March 31. ALS, also known as Lou Gehrig's Disease, is a progressive...